Study guide

14.3 Radionuclide Therapy Procedures

Certified Nuclear Medicine Technologist CNMT

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current CNMT Exam Facts 1.2 How to Use This Guide

2 Radiation Physics Fundamentals

2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles

3 Biological Effects & ALARA

3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring

4 NRC & Regulatory Compliance

4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records

5 Generators & Kit Preparation

5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control

6 Tc-99m Diagnostic Agents

6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells

7 Non-Tc Diagnostic & PET Agents

7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents

8 Therapeutics, Adjuncts & Administration

8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents

9 Non-Imaging Instrumentation

9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment

10 Imaging Systems & Quality Control

10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization

11 Pulmonary, Bone, Oncology & Infection Imaging

11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures

12 Renal, Endocrine & Hematopoietic Imaging

12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique

13 Cardiovascular Procedures

13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing

14 GI, CNS, Therapy & Hybrid CT Procedures

14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency

15 Patient Care & Clinical Workflow

15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis

14.3 Radionuclide Therapy Procedures

Key Takeaways Explain This Topic AI

Therapeutic administrations require a written directive, identity verification, activity assay, and documentation under the authorized user—technologists execute the radiation-safety and patient-care workflow

I-131 sodium iodide is used for hyperthyroidism and thyroid remnant/ablation pathways with isolation, contamination control, and NRC-style release criteria education

Lu-177 Dotatate (NET) and Lu-177 PSMA (prostate) are peptide receptor / ligand therapies with infusion protocols, antiemetic/amino-acid regimens as ordered, and post-therapy imaging when indicated

Ra-223 dichloride and Sr-89 treat bone metastases (alpha vs beta teaching); Y-90 microspheres are device/IR-coordinated hepatic radioembolization

Surveys, inpatient vs outpatient decisions, waste, room release, and patient instructions are as testable as the isotope name

Last updated: August 2026

14.3 Radionuclide Therapy Procedures

Quick Answer: Therapy day = written directive + right patient/right RP/right activity + safety controls + surveys/waste/release education . Know I-131 , Lu-177 Dotatate/PSMA , Ra-223 , Sr-89 , and Y-90 microspheres as workflows, not just brand names.

Domain II and V merge here: you are not the authorized user who independently selects therapy activity, but you own the operational chain that keeps patients, staff, public, and license conditions safe.

Universal Therapy Workflow

  • Step Tech / team actions
  • 1. Written directive Present before administration; matches patient, RP, route, activity (or formula)
  • 2. Identity & consent Two identifiers; pregnancy status for relevant ages; consent per policy
  • 3. Assay Dose calibrator measurement; residual syringe/vial after administration
  • 4. Administration Route-specific technique (oral capsule/liquid, IV infusion, IR catheter)
  • 5. Immediate safety Spill kit ready; PPE; shield; time/distance
  • 6. Surveys Patient, area, staff as required; document mR/h at set distances
  • 7. Release / isolation Apply regulatory release criteria or inpatient hold; teach hygiene
  • 8. Waste & records Decay-in-storage logs, return shipping if needed, chart all measurements

Basic dosimetry concepts (tech level): prescribed activity may come from empiric fixed amounts, weight-based activity, or pretherapy imaging (e.g., I-123/I-131 diagnostic uptake, MAA shunt fraction for Y-90). Record administered activity = assayed − residual. Post-therapy imaging (bremsstrahlung, SPECT/CT, or gamma emissions from Lu-177) verifies distribution when ordered.

I-131 Sodium Iodide (Hyperthyroid and Ablation)

  • Pathway Teaching notes
  • Hyperthyroidism Outpatient oral capsule common; lower activities than remnant ablation

Thyroid cancer remnant / ablation / treatment Higher activities; may require inpatient isolation depending on activity and release criteria

Prep: low-iodine diet and TSH stimulation pathway (withdraw thyroxine or use rhTSH) are clinical orders—confirm they were followed when the requisition requires it. Stop interfering iodinated contrast/meds per timeline. Pregnancy test documentation is mandatory in applicable patients; counsel breastfeeding cessation per policy (often prolonged).

After administration: control vomit risk early (contamination); private toilet instructions; hydrate; avoid prolonged close contact with children/pregnant persons for a protocol-defined period; separate utensils/laundry teaching as applicable. Survey the patient at 1 m (or per SOP) against release criteria (NRC-style activity or dose-rate thresholds—know that release is criteria-based, not “feelings”). Inpatient rooms: map hot spots, use disposable covers, hold trash for decay, release room only after survey clearance.

Lu-177 Dotatate (e.g., Lutathera® class teaching)

Lu-177 DOTATATE delivers beta therapy to somatostatin receptor–positive NETs. Typically given as a slow IV infusion with concurrent amino acid infusion (renal protection) and antiemetics per product labeling/protocol. Multiple cycles weeks apart are common.

  • Tech focus Detail
  • Extravasation prevention Secure IV; monitor infusion site
  • Contamination Lu-177 has gamma emissions useful for imaging but still contaminates
  • Post-therapy imaging SPECT/CT of distribution when ordered (same admission or next day)
  • Radiation precautions Time/distance/hygiene for family; follow written patient instructions
  • Labs / clinical holds Confirm AU cleared labs (marrow, renal) before you hang the dose
  • Lu-177 PSMA Ligand Therapy

Lu-177 PSMA agents treat PSMA-avid metastatic prostate cancer under authorized protocols. Workflow resembles other IV radioligand therapies: written directive, assay, controlled infusion, contamination control, possible post-therapy SPECT, and outpatient precautions focused on urinary excretion (hydrate, frequent voiding, bathroom hygiene).

Ra-223 Dichloride and Sr-89

Agent Emission teaching Clinical niche

Ra-223 dichloride Alpha emitter localizing to bone mineral Symptomatic bone mets (classic: castration-resistant prostate)

Sr-89 chloride Beta bone seeker Palliation of osteoblastic mets

Both are IV administrations with marrow-suppression risk awareness (clinical lab review is AU/clinician domain). Alpha therapy has high LET but short range—external dose rates are typically lower than high-activity I-131, yet body fluid precautions and assay/documentation still apply. Schedule serial doses (Ra-223 often every 4 weeks × 6 teaching) and verify injection site integrity.

Y-90 Microspheres (Radioembolization)

Y-90 glass or resin microspheres are delivered intra-arterially in IR after MAA mapping. Y-90 is primarily a beta emitter (bremsstrahlung imaging possible). Tech/NMT roles vary by site: assay of vial activity, documentation of delivered vs residual, radiation safety coverage in IR, post-procedure surveys of room/staff/waste, and patient release instructions. Nontarget delivery (GI ulceration risk) is prevented by IR technique—not by planar “hoping.” Coordinate with the planning MAA study results (shunt fraction).

Inpatient vs Outpatient, Waste, and Education

  • Decision driver Examples
  • Activity & isotope High I-131 more often triggers hold vs low hyperthyroid dose outpatient
  • Release criteria Dose rate / retained activity thresholds + ability to follow instructions
  • Clinical condition Incontinence, vomiting, inability to self-isolate → favor inpatient controls

Waste: segregate radioactive trash, label with date/isotope, decay-in-storage until background, survey before conventional disposal. Never send hot linen through normal laundry without clearance. Documentation wins inspections: directive, assay, residual, surveys, release teaching, and lot numbers.

Post-Therapy Imaging and “Did It Go Where Intended?”

  • Therapy Common verification
  • I-131 Whole-body post-therapy scan days later
  • Lu-177 agents SPECT/CT using Lu-177 photons
  • Y-90 Bremsstrahlung SPECT or PET (internal pair production) per capability
  • Ra-223 Limited external imaging utility—clinical/follow-up labs dominate

Bottom line for CNMT: treat therapy as a regulated procedure sequence . Name the agent class, route, major safety control, and release/education point—that is the exam-level skill set.